Share of priority review drug approval applications treating cancer
Percentage share of priority review drug approval applications targeting oncology indications.
Unit Percent Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Every record
All records
1 record · 1 region · 2020–2024
| Period | Value | Source | Type |
|---|---|---|---|
| China 1 record | |||
| end of 2024 | 42.5% | State Council · 31 Dec 2024 | actual |
Primary documents
Sources
1 document. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Measures facilitate approval of 48 first-in-class innovative drugs | State Council | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Share of priority review drug approval applications treating cancer. Retrieved from https://statorigin.org/indicators/share-of-priority-review-drug-approval-applications-treating-cancer